Sumitomo Mitsui Trust Group Inc. Sells 24,741 Shares of Encompass Health Corporation $EHC

Sumitomo Mitsui Trust Group Inc. reduced its stake in Encompass Health Corporation (NYSE:EHC) by 3.2% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 743,586 shares of the company’s stock after selling 24,741 shares during the quarter. Sumitomo Mitsui Trust Group Inc.’s holdings in Encompass Health were worth $91,186,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors have also recently made changes to their positions in the company. Invesco Ltd. lifted its stake in Encompass Health by 5.1% during the first quarter. Invesco Ltd. now owns 5,818,783 shares of the company’s stock worth $589,326,000 after purchasing an additional 282,532 shares during the last quarter. T. Rowe Price Investment Management Inc. lifted its position in Encompass Health by 25.6% in the 1st quarter. T. Rowe Price Investment Management Inc. now owns 2,080,918 shares of the company’s stock worth $210,756,000 after buying an additional 424,691 shares during the last quarter. Dimensional Fund Advisors LP boosted its stake in Encompass Health by 5.3% in the first quarter. Dimensional Fund Advisors LP now owns 1,871,581 shares of the company’s stock worth $189,549,000 after buying an additional 93,992 shares in the last quarter. Price T Rowe Associates Inc. MD grew its position in Encompass Health by 13.1% during the first quarter. Price T Rowe Associates Inc. MD now owns 1,822,376 shares of the company’s stock valued at $184,571,000 after acquiring an additional 211,707 shares during the last quarter. Finally, Fuller & Thaler Asset Management Inc. raised its stake in shares of Encompass Health by 11.9% during the first quarter. Fuller & Thaler Asset Management Inc. now owns 1,541,477 shares of the company’s stock worth $156,121,000 after acquiring an additional 163,400 shares in the last quarter. Institutional investors own 97.25% of the company’s stock.

Encompass Health Stock Performance

Shares of EHC stock opened at $126.23 on Friday. The firm has a market capitalization of $12.71 billion, a price-to-earnings ratio of 24.70, a PEG ratio of 2.21 and a beta of 0.93. The stock has a fifty day moving average of $124.23 and a 200 day moving average of $118.20. Encompass Health Corporation has a 52 week low of $87.85 and a 52 week high of $127.99. The company has a quick ratio of 1.06, a current ratio of 1.06 and a debt-to-equity ratio of 0.76.

Encompass Health (NYSE:EHC) last issued its quarterly earnings data on Wednesday, March 16th. The company reported $0.93 earnings per share (EPS) for the quarter. Encompass Health had a net margin of 9.22% and a return on equity of 17.83%. The business had revenue of $136.30 million for the quarter. Encompass Health has set its FY22 guidance at $3.83-$4.19 EPS. As a group, research analysts expect that Encompass Health Corporation will post 4.8 earnings per share for the current year.

Encompass Health Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Thursday, January 15th. Shareholders of record on Friday, January 2nd will be issued a dividend of $0.19 per share. The ex-dividend date is Friday, January 2nd. This represents a $0.76 dividend on an annualized basis and a dividend yield of 0.6%. Encompass Health’s dividend payout ratio is 14.87%.

Analyst Upgrades and Downgrades

Several research analysts have recently commented on the company. UBS Group lifted their price objective on Encompass Health from $140.00 to $150.00 and gave the stock a “buy” rating in a report on Thursday, October 2nd. KeyCorp lifted their price target on Encompass Health from $135.00 to $140.00 and gave the stock an “overweight” rating in a research note on Tuesday, September 16th. Truist Financial increased their price objective on Encompass Health from $135.00 to $140.00 and gave the company a “buy” rating in a research note on Thursday, August 14th. Bank of America lifted their target price on shares of Encompass Health from $145.00 to $160.00 and gave the stock a “buy” rating in a research note on Wednesday, September 10th. Finally, Zacks Research upgraded shares of Encompass Health from a “hold” rating to a “strong-buy” rating in a report on Tuesday, October 21st. Two analysts have rated the stock with a Strong Buy rating and eight have given a Buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Buy” and an average price target of $139.86.

Insider Activity

In other news, EVP Patrick William Tuer sold 1,020 shares of the firm’s stock in a transaction that occurred on Wednesday, August 27th. The stock was sold at an average price of $123.59, for a total value of $126,061.80. Following the completion of the transaction, the executive vice president owned 18,846 shares in the company, valued at $2,329,177.14. This trade represents a 5.13% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Corporate insiders own 2.00% of the company’s stock.

About Encompass Health

Encompass Health Corporation provides post-acute healthcare services in the United States and Puerto Rico. It owns and operates inpatient rehabilitation hospitals that provide medical, nursing, therapy, and ancillary services. The company provides specialized rehabilitative treatment on an inpatient basis to patients who have experienced physical or cognitive disabilities or injuries due to medical conditions, such as strokes, hip fractures, and various debilitating neurological conditions.